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A B S T R A C T
Auditory verbal hallucinations (AVH) are common in patients with borderline personality disorder (BPD). We
examined two candidate mechanisms of AVH in patients with BPD, suggested to underlie sensory processing
systems that contribute to psychotic symptoms in patients with schizophrenia; sensory gating (P50 ratio and P50
difference) and change detection (mismatch negativity; MMN). Via electroencephalographic recordings P50
amplitude, P50 ratio, P50 difference and MMN amplitude were compared between 23 borderline patients with
and 25 without AVH, and 26 healthy controls. Borderline patients with AVH had a significantly lower P50 dif-
ference compared with healthy controls, whereas no difference was found between borderline patients without
AVH and healthy controls. The groups did not differ on MMN amplitude.
The impaired sensory gating in patients with borderline personality disorder who experience AVH implies
that P50 sensory gating deficiencies may underlie psychotic vulnerability in this specific patient group. Patients
with borderline personality disorder with or without AVH did not have problems with auditory change detec-
tion. This may explain why they are spared from the poor outcome associated with negative symptoms and
symptoms of disorganization in patients with chronic schizophrenia.
1. Introduction
AVH also frequently occur in patients with borderline personality
disorder (BPD) (Kingdon et al., 2010; Niemantsverdriet et al., 2017;
Pearse et al., 2014; Yee et al., 2005), with a point prevalence of 21%
(Niemantsverdriet et al., 2017). Among these patients, associations
have been reported between the presence and severity of AVH and both
suicidality and hospitalization (Slotema et al., 2017). In patients with
BPD, AVH are phenomenologically similar to those in patients with
schizophrenia and cause equal amounts of distress (Kingdon et al.,
2010; Slotema et al., 2012; Tschoeke et al., 2014). This, and the
knowledge that both schizophrenia and borderline personality disorder
are often associated with childhood trauma, offers the possibility that
there may be a shared underlying mechanism of AVH in these two
(McCarthy-Jones and Longden, 2015; Niemantsverdriet et al., 2017).
To date however, no studies have investigated the neurocognitive or
neurobiological mechanisms of AVH in patients with BPD to test this
hypothesis.
In the research field of schizophrenia spectrum disorders, sensory
processing deficiencies have been mentioned to underlie psychotic
symptoms, such as hallucinations. Javitt & Freedman (Javitt and
Freedman, 2015) explain in their review that these deficits in proces-
sing auditory (or visual) stimuli may lead to psychotic symptoms in two
ways: i) neuropsychologically; a failure to register basic sensory in-
formation correctly makes poor decisions about it inevitable, and ii)
neurobiologically; the same neuronal mechanisms that register the in-
formation are utilized throughout the brain, so that deficits in neuronal
mechanisms detected in sensory areas are likely to be present also in
regions that have more complex executive functions.
The electroencephalographic (EEG) P50 gating is a widely used
measure for sensory gating and is reported to be reduced in patients
with schizophrenia (Bramon et al., 2004; de Wilde et al., 2007a, b;
Patterson et al., 2008). A second measurement of sensory processing is
change detection in auditory stimulation, as measured by mismatch
negativity (MMN) of the EEG, which is also known to be affected in
patients with schizophrenia (Erickson et al., 2016; Umbricht and Krljes,
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P50 sensory gating reflects a basic ability of a person to inhibit one's
response to the second of a pair of stimuli, hence the ability to filter out
irrelevant sensory information. In P50 sensory gating, auditory event-
related potentials (ERPs) are measured via EEG recordings, using a
double-click paradigm. Sensory gating occurs when the amplitude of
the P50 to the second click (S2) is suppressed compared to the ampli-
tude elicited by the first click (S1). Sensory gating can be exhibited with
the aid of the P50 ratio (the quotient of the P50 amplitude elicited by S2
divided by the P50 amplitude elicited by S1; S2/S1) and the P50 dif-
ference (the difference between the P50 amplitude elicited by S1 and
the P50 amplitude elicited by S2; S1-S2).
Meta-analyses have demonstrated significantly larger P50 ratios
compared to controls, in patients with schizophrenia (Bramon et al.,
2004; de Wilde et al., 2007a; Patterson et al., 2008) and their relatives
(de Wilde et al., 2007b; Earls et al., 2016) indicating that P50 sensory
gating seems to be an important candidate endophenotype for schizo-
phrenia.
A review of studies on the P50 ratio (Potter et al., 2006), revealed a
relationship between the P50 ratio and sustained attention and vigi-
lance. In addition, Smith et al. found that more effective P50 sensory
gating predicted better scores on attention tests (Smith et al., 2010) and
recently Hamilton et al. demonstrated covariations between P50 sup-
pression deficiency and attention difficulties, poorer working memory,
and reduced processing speed (Hamilton et al., 2018b). Three studies
focused specifically on the association between P50 sensory gating
deficiencies and AVH in patients with schizophrenia. These latter stu-
dies revealed significantly higher P50 ratios (i.e. more deficient sensory
gating) when AVH were present (state-dependent) (Thoma et al., 2017),
as well as a correlation between the severity of AVH and more deficient
P50 gating scores (Faugere et al., 2016; Smith et al., 2013). The finding
that P50 sensory gating deficiency is also found in patients with bipolar
disorder, mainly in patients with a history of psychosis, gave rise to the
hypothesis that deficient P50 gating is a more general indicator of
psychotic vulnerability (Cabranes et al., 2013; Olincy and Martin, 2005;
Sanchez-Morla et al., 2008; Schulze et al., 2007). This finding is in line
with conclusions drawn from studies reporting reduced P50 sensory
gating in patients with schizotypal personality disorder, i.e. that an
abnormal P50 ratio is a neurocognitive deficit across the psychosis
spectrum (Cadenhead et al., 2000, 2002; Hazlett et al., 2015).
Despite the widespread use of the P50 ratio, it is suggested that the
P50 difference may be a more reliable measurement of P50 sensory
gating. Following studies reporting low test-retest reliability coeffi-
cients for the P50 ratio, Smith et al. showed that the moderate corre-
lation between P50 amplitudes elicited by S1 and S2 and the greater
variability of P50 amplitudes elicited by S2 relative to the variability of
P50 amplitudes elicited by S1, are the psychometric reasons behind the
relatively less reliable measurement of P50 sensory gating via the S2/S1
ratio compared to the S1-S2 difference(Smith et al., 1994). In two
heritability studies, both Anokhin et al. (Anokhin et al., 2007) and
Greenwood et al. (Greenwood et al., 2007) found that the P50 differ-
ence exhibited higher heritability than the P50 ratio in both the general
population and in patients with schizophrenia. Since the present study
is the first P50 sensory gating study among patients with BPD who
experience AVH, both of these latter measures (i.e. the P50 ratio and
P50 difference) were applied.
1.2. Mismatch negativity
Mismatch negativity is the automatically and pre-attentively gen-
erated negative component of the ERP to any change in auditory sti-
mulation (Naatanen et al., 2007). MMN requires memory of a sequence
and detection of auditory variation (e.g. duration, frequency, location)
in the stimulus. A decreased MMN amplitude suggests a deficiency in
either the short-term memory storage of auditory information, or in the
registration of a change in auditory stimulation. MMN impairment is a
robust finding in studies focusing on sensory processing deficiencies in
patients with chronic schizophrenia (Erickson et al., 2016; Umbricht
and Krljes, 2005) and was found to be associated with the presence and
severity of AVH (Ford et al., 2012), as well as with negative symptoms
(Umbricht and Krljes, 2005) and worse functional outcome (Green
et al., 2009; Hamilton et al., 2018a).
MMN deficiencies are not limited to patients with a diagnosis of
schizophrenia, but have been found across the psychosis spectrum
(Randeniya et al., 2018). Individuals with a high risk state for psychosis
(ultra-high-risk; UHR) show consistent MMN deficiencies when studied
with duration auditory variation. When the change in auditory stimu-
lation was based on frequency however, both intact and deficient MMN
have been found (Randeniya et al., 2018). When compared to healthy
controls, patients with schizotypal personality disorder displayed re-
duced frequency MMN amplitude in a study by (Niznikiewicz et al.,
2009). In a comparison study of patients with paranoid and schizotypal
disorder however, Liu et al. found MMN amplitude similar to that of
healthy controls in the first group, and a higher MMN amplitude in the
second group, in response to frequency deviant tones (Liu et al., 2007).
Accumulating research also shows that patients with bipolar disorder,
albeit to a lesser degree than patients with schizophrenia, demonstrate
MMN deficiencies (Hermens et al., 2018).
1.3. ERPs in BPD
Although the processing of auditory stimuli by means of ERPs has
been investigated in patients with BPD, no study so far focused on
psychotic symptoms such as AVH. For example, Grootens et al. ex-
amined P50 sensory gating in patients with BPD and found increased
sensory gating in this patient group as compared to healthy controls due
to a higher amplitude elicited by S1 (Grootens et al., 2008). The authors
suggest that patients with BPD might have an increased physiological
predisposition to respond to new stimuli and that their ‘compensatory’
gating mechanism seems even more efficient compared with healthy
controls.
He et al. investigated MMN in patients with treatment-resistant
depression compared to i) patients with treatment-resistant depression
and comorbid BPD, ii) patients with BPD only, and iii) healthy controls
(He et al., 2010). Patients with treatment-resistant depression displayed
a higher MMN amplitude compared to the other groups, whereas for
patients with BPD the MMN amplitudes did not differ from those in
healthy controls.
The present study investigated whether patients with BPD who ex-
perience AVH have similar sensory processing deficiencies as observed
in patients with schizophrenia. Our hypothesis was that patients with
BPD and AVH would demonstrate a deficiency in the P50 ratio and
difference and a deficiency in MMN amplitude compared to patients
with BPD without AVH and also compared to healthy controls.
2. Methods
2.1. Participants
For participation the inclusion criteria were age ≥ 18 years and
sufficient mastery of the Dutch language. For patients with BPD, the
additional inclusion criteria were i) a diagnosis of BPD assessed with
the Structured Clinical Interview for DSM-IV-TR (SCID II) (First et al.,
1997); ii) no comorbid DSM-IV diagnosis of schizophrenia or schi-
zoaffective disorder according to the Comprehensive Assessment of
Symptoms and History (CASH) (Andreasen et al., 1992) or the MINI-
International Neuropsychiatric Interview (MINI PLUS 2000)
(Sheehan et al., 1998); and iii) no substance abuse (defined as alcohol
consumption of ≥ 3 units/day, daily cannabis use, or use of hard drugs
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≥1 time/month). AVH were defined as present when they occurred at
least once per week, as established with the frequency item of the AVH-
related subscale of the Psychotic Symptom Rating Scale (PSYRATS)
(Haddock et al., 1999). Healthy controls consisted of participants with
i) no presence or history of psychiatric illness as assessed by the MINI
PLUS 2000, ii) no present use of psychotropic medication, and iii) the
absence of AVH.
Participants were enrolled into this study between May 2009 and
August 2016 from the Outpatient Department for Personality Disorders
at Parnassia Psychiatric Institute (The Hague, the Netherlands) and
Rudolf Magnus Institute of Neuroscience, University Medical Center
Utrecht (the Netherlands). Patients were recruited either directly via
posters in the waiting rooms, or via their therapist who informed them
about the inclusion criteria for and content of this study.
The study was performed in accordance with relevant guidelines
and regulations, and registered and approved by the National Medical
Ethical Committee (NL1371209706). Written informed consent was
obtained from all participants. Each participant received 35 euro for
their participation.
A total of 23 patients with BPD and AVH (BPD+AVH), 26 patients
with BPD without AVH (BPD) and 25 healthy controls participated in
the study. However, because errors occurred in the MMN recordings of
three participants, this resulted in measurements for MMN in: 21 pa-
tients with BPD+AVH, 25 patients with BPD and 25 healthy controls.
2.2. Stimuli and procedure
The recordings took place at the Behavioural Laboratory of Erasmus
University Rotterdam. Participants were seated in a comfortable arm-
chair in a sound-attenuated room with dimmed lights, where the elastic
electrode head caps and electrodes were attached. Auditory stimuli
were presented through headphones.
The P50 stimuli consisted of two identical clicks: a conditioning
stimulus (S1) and a test stimulus (S2) with a fixed interstimulus interval
of 500 msec. The interval between the pairs of clicks varied randomly
between 8 and 12 s. Each participant received 60 trials. Participants
were instructed to count the clicks in silence and were asked to report
the number of clicks after finalization of the task. This was done to
exclude severe hearing deficits and assure a consistent level of en-
gagement during the task.
For MMN recordings participants were presented with 80 dB 500 Hz
‘‘frequent’’ stimuli with a duration of 55ms, with a rise and fall time of
5ms. At random times, an ‘‘infrequent’’ deviant 750 Hz tone was pre-
sented. In total, 700 stimuli were presented with a probability of oc-
currence of 0.85 for the frequent stimulus and 0.15 for the infrequent
stimulus. Every 1200ms, a stimulus was presented. Participants were
instructed to ignore the tones and to read a text from a magazine.
2.3. EEG recording and signal processing
The EEG was recorded with a BIOSEMI Active-Two amplifier
system, from 64 Ag/AgCl active electrodes mounted in an elastic cap.
Additional electrodes were placed at the two outer canthi of the eyes
and infraorbital and supraorbital regions for the detection of eye blinks
and eye movement artifacts (electrooculography; EOG). Mastoid elec-
trodes were placed for off-line re-referencing.
The EEG and EOG signals were analyzed with Brain Vision Analyzer
2 (Brain-Products GmbH, Munich, Germany). All signals were digitized
with a sample rate of 512 Hz and 24-bit A/D conversion. Data were off-
line re-referenced to the mastoid electrodes. Furthermore, EEG and
EOG activity was off-line filtered (bandpass 10–50 Hz (Jerger et al.,
1992; White and Yee, 1997; Yee et al., 1998); phase shift-free Butter-
worth filters; 24 dB/octave slope). Epochs including an EEG or EOG
change exceeding±50 µV were omitted from the averaging.
The auditory ERP waveforms had to meet the following criteria. The
mean 100ms pre-stimulus period served as baseline. The P50 was
identified as the largest positive peak between 50 and 100ms post
stimulus. The P50 ratio was calculated as the quotient of the P50 am-
plitude elicited by S2 divided by the P50 amplitude elicited by S1 (S2/
S1), the P50 difference was calculated as the difference between the
P50 amplitude elicited by S1 and the P50 amplitude elicited by S2 (S1-
S2). Outcomes of a high P50 ratio and a low P50 difference represent
impaired sensory gating. Consistent with previous studies, waveform
measurements were made at Cz for P50 (Hamilton et al., 2018b; Smith
et al., 2010, 2013; Thoma et al., 2017) and where the largest responses
were obtained (Fz and Cz for MMN) (Naatanen et al., 2004). The MMN
was obtained by subtracting the standard stimulus ERP (occurring at
the 140–170ms post-stimulus period) from the deviant stimulus
(Naatanen et al., 2004).
2.4. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics for
Windows, version 23.0 (Armonk, NY: IBM Corp). Participant char-
acteristics were compared using one-way ANOVA (for age) and chi-
square analyses (for gender, education and medication). Because of a
non-normal distribution in the dependent variables (P50 amplitudes,
P50 ratio and P50 difference), Kruskall–Wallis non-parametric tests
were used, followed by Mann–Whitney post-hoc testing. The MMN
amplitudes were compared with one-way ANOVA. A p-value of 0.05




Participant characteristics are presented in Table 1. The three
groups did not differ with regard to age, gender and education. The
groups BPD+AVH and BPD, did not differ with regard to medication
use.
3.2. ERP data
Fig. 1 presents the averaged waveforms for the P50 amplitude eli-
cited by S1 and S2. No differences could be revealed between the
Table 1






Age in years, mean (SD) 41.09 (13.01) 35.88 (9.69) 36.00
(12.75)
0.23
Female gender, n (%) 19 (82.6) 23 (88.5) 21 (84.0) 0.85a
Education, n (%)
Primary 4 (17.4) 2 (7.7) 1 (4.0) 0.28a
Vocational 11 (47.8) 15 (57.7) 9 (36.0) 0.33
Selective secondary 1 (4.3) 2 (7.7) 6 (24.0) 0.11a
Bachelor degree or
higher
5 (21.7) 4 (15.4) 9 (36.0) 0.24
Medication, n (%)
Typical AP 4 (17.4) 1 (4.3) – 0.35a
Atypical AP 4 (17.4) 7 (30.4) – 0.30
Hypnotics 8 (34.8) 6 (25.0) – 0.46
Antidepressants 13 (59.1) 12 (52.2) – 0.64
Mood stabilizers 2 (8.7) 0 (0.0) – 0.23a
Abbreviations: AP= antipsychotic, BPD+AVH=patients with borderline
personality disorder and auditory verbal hallucinations, BPD=patients with
borderline personality disorder without auditory verbal hallucinations,
HC=healthy controls.
Group differences were analyzed with one-way ANOVA for age and with chi-
square analysis for gender, education and medication.
a Fisher's exact test was used because of expected small frequencies.
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groups in the P50 amplitude (elicited by S2) and the P50 ratio (Table 2,
Fig. 2). However, there was a trend between the groups towards a
difference in the P50 amplitude elicited by S1 (H(2)=5.63, p=0.06).
There was a significant difference between the groups in the P50 dif-
ference (S2-S1) (H(2)=8.01, p=0.02). The P50 difference was
smaller for the BPD+AVH group compared to healthy controls (median
0.53 vs. 1.62, Z=−2.53, p=0.01) with a moderate effect size
(r=0.36) (Cohen, 1992). The P50 difference was also smaller for the
group BPD+AVH compared to the BPD group (median 0.53 vs. 1.62,
Z=−2.30, p=0.02). However, the latter difference did not remain
significant after Bonferroni correction.
All groups displayed MMN at both the Fz and Cz sites. No significant
differences in MMN were found between the groups (Table 3).
4. Discussion
This is the first study to investigate sensory processing deficiencies
that may contribute to the origin of auditory verbal hallucinations
(AVH) in patients with borderline personality disorder (BPD).
Following the extensive number of studies on auditory hallucinations in
patients with schizophrenia, we hypothesized that P50 sensory gating
(measured as the P50 ratio and P50 difference) and mismatch nega-
tivity (MMN) would be negatively affected in patients with BPD and
AVH, compared to patients with BPD without AVH and to healthy
controls. Indeed, the P50 difference was significantly smaller in patients
with BPD and AVH compared to healthy controls, with a moderate
effect size (r=0.36). Patients with BPD without AVH did not differ
from healthy controls with regard to the P50 difference. Also, there was
no significant difference between the three groups in P50 amplitudes,
P50 ratio, and MMN.
The P50 difference is a more sensitive measurement of P50 sensory
gating than the P50 ratio (Anokhin et al., 2007; Greenwood et al., 2007;
Smith et al., 1994). This is probably why, in the present study, P50
difference showed a deficiency in patients with BPD and AVH whereas
P50 ratio did not.
P50 sensory gating deficiency can be caused by either a defect in
gating-out the test (S2) stimulus or a defective response to the con-
ditioning (S1) stimulus (Chang et al., 2011). Chang, Arfken, Sangal &
Boutros found, through weighted random effects meta-analysis, that the
major contributor to sensory gating deficiencies is the decreased P50
amplitude elicited by S2 (effect size 0.65, compared to 0.19 for the
increased P50 amplitude elicited by S1) in studies comparing patients
with schizophrenia and healthy controls (Chang et al., 2011). At the
same time, they demonstrate a large range in P50 amplitudes in re-
sponse to S1 and a high percentage of overlapping between patients
with schizophrenia and healthy controls. The authors therefore do not
rule out a contribution of P50 amplitude elicited by S1 to sensory gating
deficiencies. This ‘gating-in’ deficit has been described in patients with
schizophrenia (Greenwood et al., 2016; Johannesen et al., 2005; Smith
et al., 2013; Zhu et al., 2017; Zouridakis et al., 1997) and schizotypal
personality disorder (Hazlett et al., 2015). Correspondingly, we found
that P50 sensory gating deficiency in patients with BPD and AVH seems
Fig. 1. Averaged waveforms for the P50 amplitude elicited by (A) S1 and by (B) S2. The lines indicate the mean values in electrode position Cz. Abbreviations: BPD
+AVH=patients with borderline personality disorder and auditory verbal hallucinations, BPD=patients with borderline personality disorder without auditory
verbal hallucinations, HC=healthy controls, S1= first stimulus, S2= second stimulus.
Table 2
Data on the P50: median (range) and test statistic.
Median (range) Post-hoc







H(2) p Z p effect size
(r)
Z p effect size
(r)
Z p effect size
(r)
P50 at Cz-site








5.63 0.06 – – – – – –




























8.01 0.02 −2.30 0.02a 0.33 −2.53 0.01b 0.36 −0.70 0.49 0.11
a No longer significant after Bonferroni correction. b Remained significant after Bonferroni correction. Abbreviations: BPD+AVH=patients with borderline
personality disorder and auditory verbal hallucinations, BPD=patients with borderline personality disorder without auditory verbal hallucinations, HC=healthy
controls.
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to be caused by a diminished response to the S1 stimulus rather than to
the S2 stimulus.
Our finding of a relationship between P50 sensory gating deficiency
and AVH was demonstrated in three earlier studies (Faugere et al.,
2016; Smith et al., 2013; Thoma et al., 2017) of patients with schizo-
phrenia. Several other studies however, could not establish a correla-
tion (Hamilton et al., 2018b) (and for a review see (Potter et al., 2006)).
These studies show that associations with cognitive performance, more
specifically attention, working memory and processing speed seem to
be more robust than associations with AVH. In a short review, Ford
mentioned a number of possible explanations for the lack of a sig-
nificant association between ERP's, including P50, and the presence of
positive or negative psychotic symptoms (Ford, 2018). For example, the
use of psychotropic medication may alter the outward presentation
(such as hallucinations) of the underlying pathology, leading to a de-
coupling of the symptoms from neurobiology. Ford also referred to the
RDoC (Research Domain Criteria) framework of the National Institute
for Mental Health (NIMH) which aims to cut across traditional disorder
boundaries and focus on basic dimensions of functioning instead
(Cuthbert and Insel, 2010). ERP's may be more beneficial in discovering
the pathophysiology of psychotic symptoms when studied in relation to
the specific domains of functioning that underlie the symptoms of in-
terest (e.g. the Cognitive Systems Domain, encompassing among others
attention and working memory) instead of in relation the specific
symptom itself.
The fact that we did find P50 sensory gating deficiency in the BPD
group who experienced AVH, as was found before in patients with
schizophrenia (de Wilde et al., 2007b; Earls et al., 2016; Patterson et al.,
2008) and patients with other diagnoses that display psychotic symp-
toms such as bipolar disorder and schizotypal disorder (Cabranes et al.,
2013; Cadenhead et al., 2000, 2002; Olincy and Martin, 2005; Sanchez-
Morla et al., 2008; Schulze et al., 2007), may imply that P50 sensory
gating not only serves as a specific endophenotype for schizophrenia,
but rather as an indication of psychotic vulnerability across diagnoses.
We therefore recommend using a transdiagnostic symptomatic ap-
proach in the research, diagnosis and treatment of AVH (Javitt, 2016;
Waters and Fernyhough, 2017).
In their review on the investigation of BPD via electrophysiological
modalities, Boutros, Torella & McGlashan mention a number of studies
that bring up the possibility of biologically distinct subtypes; i.e. an
affective and a psychotic subtype, that may be useful in guiding treat-
ment choices (Boutros et al., 2003). Future studies using biological
markers such as ERPs could be useful to disentangle specific subtypes
based on sensory processing.
In contrast to the present study, Grootens et al. found that patients
with BPD showed increased sensory gating (P50 difference) compared to
healthy controls, where we found no sensory gating differences between
patients with BPD without AVH and healthy controls (Grootens et al.,
2008). It seems Grootens et al. included a relatively healthy group of
patients with BPD, since all comorbid mood disorders with the excep-
tion of dysthymic disorder were excluded, while these disorders are
Fig. 2. Scatterplots for the P50 amplitude. The upper two graphs show the P50 amplitude elicited by (A) S1 and by (B) S2. The lower two graphs show the P50 ratio
(C; S2/S1) and the P50 difference (D; S1-S2). Please note the use of different scaling. P-values are given of significant differences (p <0.05) after Bonferroni
correction for multiple comparisons. Abbreviations: BPD+AVH=patients with borderline personality disorder and auditory verbal hallucinations, BPD=patients
with borderline personality disorder without auditory verbal hallucinations, HC=healthy controls, S1= first stimulus, S2= second stimulus.
Table 3
Data on mismatch negativity (MMN): mean (standard deviation) and test sta-
tistic.















−3.63 (2.61) −4.86 (2.63) −4.03
(2.22)
1.488 0.233
Abbreviations: MMN=mismatch negativity, BPD+AVH=patients with bor-
derline personality disorder and auditory verbal hallucinations, BPD=patients
with borderline personality disorder without auditory verbal hallucinations,
HC=healthy controls.
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known to be highly prevalent among patients with BPD (Zanarini et al.,
2004).
Mismatch negativity was not affected in patients with BPD with or
without AVH. This finding is comparable to that of He et al. who also
found that MMN amplitudes in patients with BPD were not different
from those in healthy controls (He et al., 2010).
The absence of MMN deficiency in patients with BPD and AVH may
be explained by our choice to use a frequency deviant stimulus to in-
vestigate change detection in auditory stimulation. A study by Michie
et al., investigating reasons why a minority of studies did not show
MMN deficiency in patients with schizophrenia, showed that only
duration-deviant stimuli led to significantly reduced MMN, while fre-
quency-deviant stimuli MMN showed a trend in reducing MMN, pro-
vided that large frequency deviants were used (Michie et al., 2000).
There is also another possible explanation for the absence of MMN
deficiency in patients with BPD and AVH. Although attenuated MMN
has been established in patients with chronic schizophrenia (Erickson
et al., 2016; Naatanen et al., 2014), equivocal results (with also intact
or minimally deviant MMN) were found in ultra-high-risk and first-
episode schizophrenia patients. In healthy voice hearers MMN defi-
ciencies have even been demonstrated to be absent (van Lutterveld
et al., 2010). Additionally, MMN deficiency was found to be specific for
the patients with schizophrenia that are significantly disabled and un-
able to function with or without support (Hamilton et al., 2018a). Thus,
it seems that, rather than MMN deficiency serving as a genetic vul-
nerability for the disease (schizophrenia), it might be better seen as a
marker for disease progression and poor outcome (Erickson et al., 2016;
Hamilton et al., 2018a; Umbricht and Krljes, 2005) in individuals who
experience psychotic symptoms. If we translate this hypothesis to our
group of patients with BPD and AVH in whom MMN deficiencies were
absent, this group (as are the healthy voice hearers) appears to be
spared from the poor outcome associated with negative psychotic
symptoms and symptoms of disorganization seen in patients with
chronic schizophrenia. This seems to be in line with the findings in our
previous study, demonstrating the absence of negative symptoms and
disorganization in patients with BPD and AVH, thereby distinguishing
them from patients with schizophrenia (Niemantsverdriet et al., 2017).
4.1. Study limitations
The significance of the difference between patients with BPD and
AVH and BPD without AVH with regards to P50 difference, disappeared
after Bonferroni correction. We can not rule out that this means that
these two groups do not differ in this regard and therefore the sig-
nificance for P50 difference between patients with BPD and AVH and
healthy controls is not explained by the presence of AVH. However,
observing the absolute median values for P50 difference (BPD and AVH
0.53 µV, BPD and healthy controls both 1.62 µV) does not make this
assumption very likely. Rather, we expect that the relatively small
sample sizes have prevented the results to reach statistical significance.
The sample sizes were based on an expected large effect size
(Bramon et al., 2004), instead a moderate effect size was found for P50
difference between patients with BPD and AVH and healthy controls.
The reduced P50 amplitude to the S1 stimulus for patients with BPD
and AVH may have confounded the finding of the smaller P50 differ-
ence, as the reduced P50 amplitude to the S1 stimulus creates a floor
effect for the P50 amplitude to the S2 stimulus for the patients with BPD
and AVH in contrast with the healthy controls for whom there is no
floor effect. This limitation warrants caution to draw definite conclu-
sions with regards to P50 sensory gating deficits in patients with BPD
and AVH until replications of the results with larger sample sizes are
established.
It could be argued that, in the present study, the use of psychotropic
medication by participants with BPD both with and without AVH, may
have influenced MMN thereby explaining the lack of differences com-
pared with healthy controls. Participants in the present study were
instructed not to take benzodiazepines on the day of the EEG and
chronic use of benzodiazepines does not influence this ERP component
(Kasai et al., 2002). In addition, no clear effects of antipsychotics on
MMN have been demonstrated (Umbricht and Krljes, 2005). However,
no studies have investigated the effect of mood stabilizers on MMN.
Furthermore, one study found that escitalopram did enhance MMN in
healthy participants (Wienberg et al., 2010). Therefore, an effect of
mood stabilizers or antidepressants on MMN cannot be fully ruled out.
Also, as there may be a normalizing effect of smoking on P50 sen-
sory gating and the effects of nicotine are short-lived, it is advised not to
let participants smoke before testing (de Wilde et al., 2007b). We did
not control for smoking and did not instruct our participants not to
smoke before the testing. However, before testing, filling in the ques-
tionnaires and preparing the participant for the test took about 1–2 h,
which may be long enough to allow any possible effects of nicotine to
subside.
4.2. Recommendations for research
Replication studies are necessary to establish that sensory gating
deficiencies are indeed a consistent finding in patients with BPD ex-
periencing AVH. Since the sound intensity of the stimuli correlates with
the effect size of P50 suppression (de Wilde et al., 2007a), we re-
commend that future studies use a standard stimulus of 15 dB above the
hearing threshold (Griffith et al., 1995). In addition, increased sound
intensities can be used to elicit larger P50 amplitudes. This might yield
more distinctive results and provide more insight into whether P50
sensory gating deficiency in patients with BPD and AVH is caused by a
‘gating-in’ (a diminished response to the S1 stimulus) or a ‘gating-out’
(suppression of the response to the S2 stimulus) deficit. Also, a direct
comparison with patients with schizophrenia might reveal whether P50
sensory gating is impaired to the same (or to a lesser) extent in patients
with BPD and AVH. For example, less impairment was found in patients
with schizotypal personality disorder, which the authors attributed to
possible protective factors, such as frontal lobe sparing (Hazlett et al.,
2015).
Furthermore, P50 sensory gating deficiency has been found in pa-
tients with post-traumatic stress disorder (PTSD) (Javanbakht et al.,
2011; Karl et al., 2006) and is now also demonstrated in patients with
BPD and AVH. Patients with BPD and AVH display a higher prevalence
of PTSD than patients with BPD without AVH (Niemantsverdriet et al.,
2017). These findings may imply that traumatic experiences are a
causal factor in the development of P50 sensory gating deficiency
leading to psychotic symptoms. Although this relationship between
(childhood) trauma and the development of psychotic symptoms is
widely acknowledged (McCarthy-Jones and Longden, 2015;
Niemantsverdriet et al., 2017; Varese et al., 2012), the exact etiological
routes remain to be elucidated.
In addition, we need to examine whether attention, working
memory and processing speed (which are associated with P50 sensory
gating deficiency in patients with schizophrenia) also play a role in the
experience of AVH in patients with BPD, and whether interventions
aimed at improving attention and working memory can improve P50
sensory gating and decrease the distress/dysfunction caused by AVH
(Popov et al., 2011). Transcranial direct current stimulation (tDCS) is
another possible treatment aimed at modulating P50 sensory gating to
improve auditory hallucinations, which may be worth investigating
when more definite results in patients with schizophrenia become
available (Kim et al., 2018). Finally, in view of the positive effects of
clozapine on P50 sensory gating (Adler et al., 2004; Becker et al., 2004;
Nagamoto et al., 1999; Simosky et al., 2003), it is important to examine
whether this effect can also be achieved in patients with BPD and AVH,
and whether improved P50 sensory gating leads to diminishment of
AVH in this patient group.
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